Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance

K Kaku, T Kadowaki, Y Terauchi, T Okamoto, A Sato, K Okuyama, J C Arjona Ferreira, B J Goldstein, K Kaku, T Kadowaki, Y Terauchi, T Okamoto, A Sato, K Okuyama, J C Arjona Ferreira, B J Goldstein

Abstract

Aims: To evaluate the efficacy and tolerability of sitagliptin in subjects with impaired glucose tolerance (IGT).

Methods: In a double-blind, parallel-group study, 242 Japanese subjects with IGT, determined by a 75-g oral glucose tolerance test (OGTT) at week -1, were randomized (1 : 1 : 1) to placebo (n = 83), sitagliptin 25 mg (n = 82) or 50 mg (n = 77) once daily for 8 weeks. Glycaemic variables were assessed using another OGTT at week 7 and meal tolerance tests (MTTs) at weeks 0 and 8. Primary and secondary endpoints were percent change from baseline in glucose total area under the curve 0-2 h (AUC(0 -2 h)) during the MTT and OGTT, respectively.

Results: Least squares mean percent change from baseline in glucose AUC(0 -2 h) during the MTT were -2.4, -9.5 and -11.5%, and during the OGTT were -3.7, -21.4 and -20.1% with placebo, sitagliptin 25 mg once daily, and 50 mg once daily, respectively (p < 0.001 for either sitagliptin dose vs placebo in both tests). Sitagliptin treatment enhanced early insulin response during the OGTT and decreased total insulin response, assessed as the total AUC(0 -2 h) during the MTT. Sitagliptin treatment also suppressed glucagon response during the MTT. The incidence of adverse events, including hypoglycaemia, was low and generally similar in all treatment groups.

Conclusions: Treatment with sitagliptin significantly reduced glucose excursions during both an MTT and an OGTT; this effect was associated with an increase in early insulin secretion after oral glucose loading as well as a blunted glucagon response during an MTT. Sitagliptin was generally well tolerated in subjects with IGT.

Trial registration: ClinicalTrials.gov NCT01405911.

Keywords: DPP-4; MK-0431; dipeptidyl peptidase-4 inhibitors; incretins.

© 2015 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Patient disposition. q.d., once daily; ALT, alanine aminotransferase. aAn additional 19 subjects, including 9 who were randomized (3, 4, and 2 subjects in placebo, sitagliptin 25 and 50 mg q.d. groups, respectively), are not included in this disposition accounting and were not included in study analyses because the site at which they were enrolled was identified as noncompliant with some requirement of Good Clinical Practice and therefore data from this site were deemed to be unreliable. bDiscontinuation due to ALT increased at baseline (not on treatment).
Figure 2
Figure 2
Treatment effects on plasma glucose (A), insulin (B) and glucagon (C) levels during meal tolerance test (MTT) at baseline () and at week 8 of treatment () and on glucose (D) and insulin (E) during oral glucose tolerance test (OGTT) at baseline () and at week 7 of treatment (). Data shown are mean ± standard error.

References

    1. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183–1197.
    1. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2‐hour diagnostic criteria. Arch Intern Med 2001; 161: 397–405.
    1. Nakagami T; DECODA Study Group . Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004; 47:385–394.
    1. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata diabetes study. Diabetes Care 1999; 22: 920–924.
    1. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427–2443.
    1. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321: 405–412.
    1. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. J Am Med Assoc 1999; 281: 2005–2012.
    1. Gerstein HC, Santaguida P, Raina P et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta‐analysis of prospective studies. Diabetes Res Clin Pract 2007; 78: 305–312.
    1. Rosenstock J. Reflecting on type 2 diabetes prevention: more questions than answers!. Diabetes Obes Metab 2007; 9(Suppl. 1): 3–11.
    1. Knowler WC, Barrett‐Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
    1. Gerstein HC, Yusuf S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096–1105.
    1. DeFronzo RA, Tripathy D, Schwenke DC et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364: 1104–1115.
    1. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP‐NIDDM randomised trial. Lancet 2002; 359: 2072–2077.
    1. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double‐blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009; 373: 1607–1614.
    1. Standards of medical care in diabetes‐2015. Diabetes Care 2015; 38 (Suppl. 1):S1–S94.
    1. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet Med 2007; 24: 451–463.
    1. Evidence‐Based Practice Guideline for the Treatment of Diabetes in Japan 2013. Tokyo: Nankodo Co., Ltd, 2013.
    1. Xu L, Man CD, Charbonnel B et al. Effect of sitagliptin, a dipeptidyl peptidase‐4 inhibitor, on beta‐cell function in patients with type 2 diabetes: a model‐based approach. Diabetes Obes Metab 2008; 10: 1212–1220.
    1. Brazg R, Xu L, Dalla MC, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase‐4 inhibitor, to metformin on 24‐h glycaemic control and beta‐cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 186–193.
    1. Rosenstock J, Foley JE, Rendell M et al. Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008; 31: 30–35.
    1. Hage C, Brismar K, Efendic S, Lundman P, Ryden L, Mellbin L. Sitagliptin improves beta‐cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities‐the BEGAMI study. J Intern Med 2013; 273: 410–421.
    1. Kashiwagi A, Kasuga M, Araki E et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest 2012; 3: 39–40.
    1. Tatosian DA, Guo Y, Schaeffer AK et al. Dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Ther 2013; 4: 431–442.
    1. Liang KY, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre‐post designs. Indian J Stat 2000; 62: 134–148.
    1. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4: 213–226.
    1. Thornberry NA, Weber AE. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr Top Med Chem 2007; 7: 557–568.
    1. U.S. prescribing information for JANUVIA® (sitagliptin) tablets. February 2014. Available from URL: . Accessed 22 October 2014.
    1. Mitrakou A, Kelley D, Mokan M et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 326: 22–29.
    1. Herman GA, Bergman A, Stevens C et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase‐4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612–4619.
    1. Engel SS, Round E, Golm GT, Kaufman KD, Goldstein BJ. Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. Diabetes Ther 2013; 4: 119–145.
    1. Bock G, Dalla MC, Micheletto F et al. The effect of DPP‐4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol (Oxf) 2010; 73: 189–196.
    1. Utzschneider KM, Tong J, Montgomery B et al. The dipeptidyl peptidase‐4 inhibitor vildagliptin improves beta‐cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 2008; 31: 108–113.
    1. Ahren B. Use of DPP‐4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Metab Syndr Obes 2010; 3: 31–41.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe